Topotecan, High-Dose Cyclophosphamide, Carboplatin, and an Autologous Peripheral Blood Cell Transplant in Treating Patients With Recurrent Ovarian Cancer or Primary Peritoneal Cancer

Exclusion Criteria

• •PATIENT CHARACTERISTICS:
• •ECOG performance status 0-2
• •Creatinine ≤ 1.5 mg/dL
• •Total bilirubin ≤ 2.0 mg/dL (≤ 5.0 mg/dL with metastatic disease)
• •AST ≤ 2 times upper limit of normal (ULN) (≤ 600 units/mL with metastatic disease)
• •Alkaline phosphatase ≤ 2 times ULN (unless related to metastatic disease)
• •ANC ≥ 1,000/mm\^3
• •Platelets ≥ 100,000/mm\^3
• •Cardiac ejection fraction ≥ 45% by rest ECHO or MUGA
• •FEV\_1 ≥ 50% of predicted
• •HIV negative
• •No uncontrolled infection
• •No severe medical or psychiatric illness, including any of the following:
• •* Renal failure
• •* Brittle insulin dependent diabetes mellitus
• •* Congestive heart failure
• •* History of myocardial infarction within the past 3 months
• •* Significant arrhythmia requiring medication
• •* Poorly controlled hypertension (diastolic blood pressure \>100 mm Hg)
• •* History of hospitalization for severe depression or psychosis
• •* Significant non-neoplastic pulmonary disease
• •* Current alcohol or drug abuse.
• •* Active infection
• •* Active peptic ulcer disease
• •No prior malignancy within the past 5 years except adequately treated basal cell or squamous cell carcinoma of the skin or in situ cervical carcinoma
• •PRIOR CONCURRENT THERAPY:
• •See Disease Characteristics
• •No more than 1 prior treatment regimen for this cancer
• •More than 3 weeks since surgery
• •No prior topotecan hydrochloride